純鹼、氯化銨銷售價格同比上漲 雙環科技(000707.SZ)前三季度淨利預增474.73%-529.85%
格隆匯10月10日丨雙環科技(000707.SZ)公佈2022年前三季度業績預吿,公司預計實現2022年前三季度歸屬於上市公司股東的淨利潤7.3億元-8億元,同比增長474.73%-529.85%;預計實現扣除非經常性損益後的淨利潤7.19億元-7.89億元,同比增長495.8%-553.81%。
報吿期內,公司經營業績同比大幅增長,主要原因系:
1.報吿期內,公司主要產品純鹼、氯化銨銷售價格同比上漲,毛利率同比增加,產品盈利能力大幅提升;
2.2021年7月份公司完成重大資產重組使金融負債減少及報吿期內主動歸還部分銀行貸款,導致本期財務費用大幅減少。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.